Predict your next investment

HEALTHCARE | Drug Development
cerebain.com

See what CB Insights has to offer

Stage

Acquired | Acquired

About Cerebain Biotech

Cerebain Biotech is an early stage drug development company focused on the treatment of Alzheimer's disease. The company takes an approach by developing a disease-arresting drug as compared to the current disease-inhibitors that are available today.In March 2012, Cerbain Biotech was acquired by Discount Dental Materials through a reverse merger. The valuation of Cerbain Biotech was undisclosed. Other terms of the deal were not released.As a result of the transaction, Cerebain is a wholly-owned subsidiary of the Company.

Cerebain Biotech Headquarter Location

92 Corporate Park Suite C141

Irvine, California, 92606,

United States

949-415-7478

Latest Cerebain Biotech News

Cerebain Biotech Provides Update On Share Exchange Agreement With PKG, Inc.

Apr 26, 2021

Cerebain Biotech Provides Update On Share Exchange Agreement With PKG, Inc. Cerebain Biotech Corp. (OTC: CBBT) (the "Company" or "Cerebain") today provided an update pertaining to the Share Exchange Agreement with PKG, Inc. Author: Apr 26, 2021 11:24 AM EDT Cerebain Biotech Corp. (OTC: CBBT) (the "Company" or "Cerebain") today provided an update pertaining to the Share Exchange Agreement with PKG, Inc., an Idaho Corporation (PKG) and the equity holders of PKG. Pursuant to the Share Exchange Agreement, signed on February 12, the purchase price for PKG is approximately $2.34 Million payable in shares of Cerebain's common stock at a price of $0.07 per share or an aggregate of approximately 33.47 Million shares. Cerebain has agreed to file a registration statement within 6 months of the closing to register the resale of the common stock issued to the PKG equity holders and to use its reasonable best efforts to have the registration statement declared effective, as soon thereafter as practicable. The Share Exchange Agreement requires Cerebain to pay off certain PKG liabilities in the amount of approximately $3.91 Million. Cerebain will have this amount paid on or before May 5, 2021. Approximately $1.61 Million in liabilities will remain on the books of PKG after the aforementioned payments are completed. During the term of the negotiation of the Share Exchange Agreement, Cerebain has paid an aggregate of $1,275,000 to PKG to pay certain liabilities. About Cerebain Biotech Corp.Cerebain Biotech Corp. (OTC: CBBT) is a development-stage medical device company focused on the creation and clinical development of a minimally invasive implantable device and a synthetic drug solution. The device leverages the clinically observable, positive impact that Omentum stimulation has on cognitive function as related to dementias, and in particular, Alzheimer's disease. The corporate vision is based on these positive clinical observations. Visit us at www.cerebain.com or connect with us on Twitter and Facebook to learn more. About PKG, Inc.PKG, Inc. was established in 1989 and is based in Meridian, ID. PKG, Inc. specializes in contract design, development, and manufacturing of system-level devices with expertise in human-machine interfaces. With experience in medical, aerospace, government, and industrial products, PKG helps raise your company to the next level by leveraging its engineering and technology integration skills across your product lines. With a complete in-house vertical integration of expertise, services, manufacturing processes, and technologies, PKG provides its customers with all of their product development and manufacturing needs. Besides its expertise in system-level devices and human-machine interfaces, PKG also offers incubation and acceleration services for startup businesses and entrepreneurs. For more information visit, www.pkguis.com Forward-Looking StatementsThis news release contains certain "forward- looking statements." Forward-looking statements are based on current expectations and assumptions and are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified, and many of which are beyond the Company's control. The forward-looking statements are also identified through the use of words "believe," enable," "may," "will," "could," "intends," "estimate," "anticipate," "plan," "predict" "probable," "potential," "possible," "should," "continue," and other words of similar meaning. Actual results could differ materially from these forward-looking statements as a result of a number of risk factors detailed in the Company's reports filed with OTC Markets. Given these risks and uncertainties, investors are cautioned not to place undue reliance on such forward-looking statements and no assurances can be given that such statements will be achieved. View source version on businesswire.com: https://www.businesswire.com/news/home/20210426005639/en/ By

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Cerebain Biotech

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Cerebain Biotech is included in 2 Expert Collections, including Pharma Startups.

P

Pharma Startups

6,549 items

Pharmaceutical companies working across drug discovery, drug development and drug manufacturing.

N

Neuroscience

2,144 items

Companies developing products that monitor, analyze, protect, or otherwise influence the structure/function of the nervous system.

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.